{"date":"2025-08-09","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6586-2025-08-09-1744-ybtxox","company_id":"6586","company":"醣基","market":"興櫃","industry":"生技醫療","date":"2025-08-09","time":"17:44:34","subject":"本公司研發之醣抗原抗體抗癌新藥(簡稱:CHO-A04)獲美國食品藥物管理局(FDA)核准進行一期人體臨床試驗","clause":"第44款","fact_date":"2025-08-09","cite_as":"公開資訊觀測站重大訊息：醣基（6586），2025-08-09 17:44，「本公司研發之醣抗原抗體抗癌新藥(簡稱:CHO-A04)獲美國食品藥物管理局(FDA)核准進行一期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}